Research indicates that vasoactive intestinal peptide (VIP) significantly reduces inflammation throughout the body, with particularly promising effects in conditions such as neurodegenerative diseases, pulmonary fibrosis, inflammatory bowel disease, and cardiac fibrosis. VIP appears to exert strong antifibrotic activity across several pathways, making it a promising candidate for addressing fibrosis—a common pathological process underlying many chronic and life-threatening diseases.

In addition to its antifibrotic properties, VIP functions as a potent immunomodulator and broad-spectrum anti-inflammatory agent. It has demonstrated neuroprotective effects, helping to shield the central nervous system from damage. These properties have sparked interest in VIP as a potential therapeutic tool for preserving cognitive function in the context of neurodegenerative conditions.